HCA Price Prediction Next Week
Analysis and Insights
To predict the stock price of HCA Healthcare (HCA) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
HCA's stock is currently trading near its lower Bollinger Band, suggesting potential volatility. The RSI (14) is at 53.71, indicating a neutral position, while the MACD is slightly bullish but showing signs of weakness. The stock is below its 50-day and 200-day moving averages, reinforcing a bearish trend.
Fibonacci Levels:
The Fibonacci pivot point is at 327.66, with resistance levels at 341.58 and 350.18, and support levels at 313.74 and 305.14. This suggests that if HCA breaks above the pivot, it may test the first resistance level.
News Sentiment:
HCA presented at the Barclays Global Healthcare Conference on March 11, which could positively impact investor sentiment. Additionally, HCA's Q4 earnings exceeded expectations, showing revenue growth of 5.7% and EPS of $6.22, beating estimates by 4.2%.
Price Prediction:
Based on the analysis, HCA's stock is expected to trade between 318 and 335 next week. The stock may experience a slight bounce due to its position near the lower Bollinger Band, but overall, the bearish trend is likely to continue.
Recommendation:
Sell HCA at the current price of 327.66, targeting a price of 318 as the next support level. Consider buying if the stock breaks above the Fibonacci pivot point of 327.66 and shows signs of a bullish reversal.
HCA Similar Chart Price Prediction
The price of HCA is predicted to go up 7.74%, based on the high correlation periods with OMC. The similarity of these two price pattern on the periods is 91.26%.
HCA
OMC
Up: 7.74%Similarity: 91.26%
HCA Revenue Forecast
HCA EPS Forecast
HCA FAQs
What is HCA revenue forecast for next quarter？
What is HCA eps forecast for next quarter？
HCA VS S&P500
Beyond administrative function efficiency, HCA's large scale gives it an opportunity to test and expand best practices throughout its network of facilities to improve service quality and efficiency.
HCA's focus on attractive geographic locations gives it a volume tailwind that should positively affect its top line.
The company's financial leverage should be easily manageable, giving HCA flexibility for U.S. healthcare policy changes or other shocks to the system that could constrain demand for the more elective, and highly profitable, parts of its business.
HCA Analyst's Forecast
Tim Rezvan
Keybanc
Buy
2025-01-07
Price Target
$420 → $370
Upside
+20.05%
KeyBanc analyst Matthew Gillmor lowered the firm's price target on HCA Healthcare to $370 from $420 and keeps an Overweight rating on the shares. The firm says that its revised price target reflects elevated policy uncertainty under the incoming Trump administration.
David Macdonald
Truist Securities
Strong Buy
2025-01-06
Price Target
$430 → $390
Upside
+31.35%
Craig Hettenbach
Morgan Stanley
Hold
2024-12-17
Price Target
$406 → $355
Upside
+15.34%
